CRISPR Therapeutics AG(CRSP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:11 PM ET (Korea 10/30 08:11)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.76 | Insider Own | 7.16% | Shs Outstand | 96.7M | Perf Week | 8.54% |
| Market Cap | 5.25B | Forward P/E | - | EPS next Y | 23.7% | Insider Trans | -1.39% | Shs Float | 89.8M | Perf Month | -1.92% |
| Enterprise Value | 3.67B | PEG | - | EPS next Q | -1.04 | Inst Own | 73.34% | Short Float | 18.32% | Perf Quarter | 13.07% |
| Income | -0.45B | P/S | 391.83 | EPS this Y | 32.62% | Inst Trans | -1.38% | Short Ratio | 10.7 | Perf Half Y | 3.67% |
| Sales | 0.01B | P/B | 3 | EPS next 5Y | 32.28% | ROA | -19.28% | Short Interest | 16.44M | Perf YTD | 3.47% |
| Book/sh | 18.07 | P/C | 2.22 | EPS past 3/5Y | 8.21% -4.1% | ROE | -26.09% | 52W High | -17.76% ($65.98) | Perf Year | -13.27% |
| Cash/sh | 24.46 | P/FCF | - | Sales past 3/5Y | 43.09% 37.31% | ROIC | -17.96% | 52W Low | 22.98% ($44.12) | Perf 3Y | 40.06% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 12.2% | Gross Margin | -1510.66% | Volatility(W/M) | 4.75% 5.05% | Perf 5Y | -40.59% |
| Dividend TTM | - | EV/Sales | 273.75 | Sales Y/Y TTM | -64.8% | Oper. Margin | -3971.53% | ATR (14) | 2.58 | Perf 10Y | 224.13% |
| Dividend Ex-Date | - | Quick Ratio | 17.85 | EPS Q/Q | 60.57% | Profit Margin | -3368.72% | RSI (14) | 56 | Recom | 1.87 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.85 | Sales Q/Q | 1041.37% | SMA20 | 4.93% ($51.71) | Beta | 1.91 | Target Price | $82.95 |
| Payout | - | Debt/Eq | 0.45 | Earnings | 2026/8/3 | SMA50 | -0.12% ($54.33) | Rel Volume | 0.84 | Prev Close | $54.11 |
| Employees | - | LT Debt/Eq | 0.44 | EPS/Sales Surpr. | 21.31% 36.69% | SMA200 | 2.55% ($52.91) | Avg Volume(3M) | 1.54M | Price | $54.26 |
| IPO | 2016/10/19 | Option/Short | Yes/Yes | Trades | 15065 | Volume | 1,288,758 | Change | 0.28% |
🧬 A biotech company developing therapeutics using gene-editing technology. Leveraging its gene scissors technology, the company has launched a gene therapy for a rare blood disorder in partnership with a major pharmaceutical company, and is expanding its pipeline into cardiovascular, oncology, and diabetes treatments. Revenue from its launched therapy and progress in clinical pipelines are key drivers of its value.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
CRSP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $39,183. Peers typically go for $1,632.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -40.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 73.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #51 of 594 in the industry
Based on market cap of $5B.
PTCT#49 PTC Therapeutics Inc $5B PER - 
SRRK#50 Scholar Rock Holding Corp $5B PER - CRSP#51 CRISPR Therapeutics AG $5B PER - 
ERAS#52 Erasca Inc $5B PER - 
DFTX#53 Definium Therapeutics Inc $5B PER - 
FAQ
What kind of company is CRSP?
CRSP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRSP?
The market cap of CRSP is approximately $5.2B, ranking 1,354 within its sector.
What is the 52-week high and low for CRSP?
CRSP has recorded a 52-week high of $65.98 and a low of $44.12.
